The present invention provides an epitope peptide derived from DEPDC1 having cytotoxic T cell inducing ability. The present invention also provides a polynucleotide encoding the peptide, an antigen-presenting cell presenting the peptide and a cytotoxic T cell targeting the peptide, and a method for inducing the antigen-presenting cells or the CTL. The present invention further provides pharmaceutical compositions and compositions containing the same as an active component. Furthermore, the present invention provides a method for treating and/or preventing cancer, and/or a method for preventing the post-operative recurrence of cancer, using this peptide, polynucleotide, antigen-presenting cell, or cytotoxic T cell, or using this pharmaceutical composition. Further provided is a method for inducing an immune response to cancer.本發明提供具有細胞毒性T細胞誘導能力之來自DEPDC1的抗原決定位胜肽。本發明並提供編碼為該胜肽之多核苷酸、呈現該胜肽之抗原呈現細胞及以該胜肽為標靶之細胞毒性T細胞、及誘導該抗原呈現細胞或該CTL之方法。本發明更包含以該等作為有效成分之組合物及藥學組合物。本發明更提供使用本發明之胜肽、多核苷酸、抗原呈現細胞、細胞毒性T細胞、或本發明之藥學組合物來治療及/或預防癌，及/或預發術後之癌再發之方法。又，提供誘導對於癌之免疫應答之方法。
